Nascent Biotech, Inc. NBIO

NBIO Company Overview

Nascent Biotech, Inc. is a U.S.-based biotechnology company focused on the research, development, and potential commercialization of monoclonal antibody therapeutics for oncology indications. The company operates within the biotechnology and pharmaceutical development industries, with its primary strategic emphasis centered on immunotherapy and targeted cancer treatment approaches. Public filings and company disclosures identify its lead therapeutic candidate as Pritumumab, a human monoclonal antibody being evaluated primarily for brain cancer and other tumor-related applications.

The company’s business model is largely driven by clinical development activities, intellectual property development, licensing potential, and capital raising associated with advancing therapeutic candidates through regulatory pathways. Nascent Biotech has historically positioned itself as a development-stage biotechnology enterprise rather than a revenue-generating commercial pharmaceutical company. Its strategic positioning has focused on proprietary antibody technology and the potential differentiation of naturally derived monoclonal antibody therapies within oncology markets.